Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells
Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune d...